Amazon Rolls Out Home Diagnostic Services in 6 Major Indian Cities

Amazon India expanded its healthcare services further with the launch of Amazon Diagnostics, an in-home diagnostic testing service to deliver quick, secure, and easy lab testing to the doorsteps of customers.

Meril Launches MyClip, India's First Transcatheter-Edge-to-Edge Repair (TEER) System for Treatment of Severe Mitral Regurgitation

Meril Life Sciences, a leading global med-tech company, marked a significant milestone with the launch of MyClip, India’s first Transcatheter Edge-To-Edge Repair (TEER) system

CII to Hold Hyderabad Meet on Pharma & Chemical Safety

On June 25, 2025, the Confederation of Indian Industry (CII), Telangana will hold a day-long conference, ‘Pillars of Protection – Forging a Safer Future for Pharma and Chemical Manufacturing’ in Hyderabad...

Lilly's Oral Obesity Drug Shows Promise in Phase-III Diabetes Trial

Building on the strong momentum of Mounjaro’s rollout in India, Eli Lilly has reported encouraging clinical trial results for its oral anti-obesity drug, Orforglipron. The new once-daily pill, part of the same GLP-1 drug class as Mounjaro and Zepboun

Lilly Reports Strong Mounjaro Uptake in India, Eyes Expansion

Following its prior report on the clinical success of Mounjaro, Eli Lilly has confirmed a considerable commercial response for the drug in India - the need for effective obesity and diabetes treatment is...

FDA Approves Gilead's Biannual HIV Shot for Long-Term Protection

In a HIV prevention milestone, the US Food and Drug Administration (FDA) has approved Gilead Sciences' lenacapavir, a twice-a-year long-acting injection, for adults and adolescents at risk of HIV infection.

Discovery Park Startup Showcase Sparks Entrepreneurial Energy at London Biotechnology Show 2025

The Discovery Park Startup Showcase took centre stage at the London Biotechnology Show 2025, sparking dynamic conversations and real-time feedback between emerging biotech entrepreneurs and seasoned investors.

Natco Pharma's Hyderabad unit gets 7 USFDA Form 483 observations

Natco Pharma announced on Thursday that it received a Form 483 from the United States Food and Drug Administration (USFDA) with seven observations following an inspection of its pharmaceutical division in Hyderabad...

Pharma upgrade drive: IPA-Mysuru backs Revised Schedule M rollout

With the updated Schedule M guidelines representing significant compliance issues for small and medium pharmaceutical units, the Mysuru pharma industry has taken a joint initiative to try and prepare for it...

Eli Lilly Plans Appeal Over UK Refusal to Fund Kisunla Drug

Eli Lilly said on Thursday it would appeal against a UK agency's recommendation to not reimburse the cost of Alzheimer's drug Kisunla, blocking access for patients seeking treatment under the country...

© 2025 India Pharma Outlook. All Rights Reserved.